UBS Group
RNAZ icon

UBS Group’s TransCode Therapeutics RNAZ Stock Holding History

UBS Group’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$71.4K Buy
8,295
+5,331
+180% +$49.7K ﹤0.01% 7173
2025
Q4 		$20.2K Buy
+2,964
New +$30.4K ﹤0.01% 7766
2025
Q3 		– Sell
-1,432
Closed -$11.2K – 10831
2025
Q2 		$11.2K Sell
1,432
-7,994
-85% -$74K ﹤0.01% 8797
2025
Q1 		$131K Buy
9,426
+9,116
+2,941% +$1.17M ﹤0.01% 6836
2024
Q4 		$29.2K Buy
+310
New +$115K ﹤0.01% 7624
2024
Q3 		– Sell
-81
Closed -$75.3K – 9980
2024
Q2 		$75.3K Buy
+81
New +$72.1K ﹤0.01% 6375
2024
Q1 		– Hold
0
– -$1.3K – 9913
2023
Q4 		– Sell
-4
Closed -$45K – 8347
2023
Q3 		$73.7K Buy
+4
New +$251K ﹤0.01% 6043
2023
Q1 		– Hold
0
– -$777 – 10257
2022
Q4 		– Hold
0
– – – 10073
2022
Q2 		– Hold
0
– -$11K – 10839
2022
Q1 		– Hold
0
– – – 8316
2021
Q4 		– Hold
0
– – – 8470
2021
Q3 		– Hold
0
– – – 7428

Other funds holding RNAZ

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

UBS Group's RNAZ Position: Q1 2026 in Review

UBS Group increased its TransCode Therapeutics (RNAZ) stake by 180% in Q1 2026, buying an estimated $49.7K and bringing the position to 8,295 shares worth $71.4K. The position accounts for ﹤0.01% of the portfolio, ranked #7173.

UBS Group first reported a position in RNAZ in Q3 2023 and has held it in 7 quarters since. The position peaked at $131K in Q1 2025. 8 funds tracked by Wall St. Rank hold RNAZ as of Q1 2026.

  • UBS Group held 8,295 shares of TransCode Therapeutics worth $71.4K as of Q1 2026.
  • UBS Group bought 5,331 TransCode Therapeutics shares in Q1 2026, an estimated $49.7K.
  • TransCode Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7173 holding.
  • UBS Group first reported a position in TransCode Therapeutics in Q3 2023 and has held it in 7 quarters since.
  • UBS Group's TransCode Therapeutics position peaked at $131K in Q1 2025.
  • 8 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.